Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01917968 · ClinicalTrials.gov registry record · NA
Uphold LITE Post-Market Surveillance Study
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 289
- Enrollment target
NCT01917968: Completed NA study, sponsored by Boston Scientific Corporation.
NCT01917968 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 289 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01917968, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 289 participants
- Enrollment target
Study Summary
The purpose of this study is to compare transvaginal mesh repair to traditional native tissue repair in women surgically treated for anterior and/or apical pelvic organ prolapse.
Primary Outcome
Success based on a composite of objective and subjective measures: 1. Objective success was achieved by the subject having an anatomic outcome defined as the leading edge of prolapse at or above the hymen in the operated compartment: * Anterior segment: Leading edge of anterior prolapse was at or above the hymen or POP-Q point Ba ≤ 0. * Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C \< -1/2 TVL) for multi-compartment prolap
Interventions
- DEVICE Uphold Lightweight Vaginal Support System
- PROCEDURE Traditional native tissue repair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2020-02-12 |
| Phase | NA |
What the finished NCT01917968 record still lists
NCT01917968 is an interventional study that assigns participants to a tested intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Uphold Lightweight Vaginal Support System is the first listed.
NCT01917968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01917968 about?
NCT01917968 is a clinical study titled "Uphold LITE Post-Market Surveillance Study". The purpose of this study is to compare transvaginal mesh repair to traditional native tissue repair in women surgically treated for anterior and/or apical pelvic organ prolapse.
What is the current status of trial NCT01917968?
This trial is currently completed. It is a NA study. The enrollment target is 289 participants. The study started on 2013-10-10. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT01917968?
The interventions under investigation include: Uphold Lightweight Vaginal Support System (DEVICE), Traditional native tissue repair (PROCEDURE).
Who is sponsoring clinical trial NCT01917968?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01917968's enrollment target sits among peer trials
289 376th of 2000 higher than 1,625 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI